Syndax Pharmaceuticals (FRA:1T3) Net Margin %: -65.79% (As of Mar. 2026)


FRA:1T3 Syndax Pharmaceuticals Inc FRA:1T3
25 GF Score
Price €17.43
! 7 Warning Signs
View Full Analysis

What is Syndax Pharmaceuticals Net Margin %?

Syndax Pharmaceuticals FRA:1T3 -0.94% 25 Net Margin % is -65.79% as of Mar. 2026. GuruFocus rates FRA:1T3 with a GF Score™ of 25/100. The stock has 7 warning signs investors should review. Among 946 Biotechnology companies, Syndax Pharmaceuticals ranks worse than 52.22% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Syndax Pharmaceuticals's Net Income for the three months ended in Mar. 2026 was €-36.9 Mil. Syndax Pharmaceuticals's Revenue for the three months ended in Mar. 2026 was €56.1 Mil. Therefore, Syndax Pharmaceuticals's net margin for the quarter that ended in Mar. 2026 was -65.79%.

The historical rank and industry rank for Syndax Pharmaceuticals's Net Margin % or its related term are showing as below:

FRA:1T3' s Net Margin % Range Over the Past 10 Years
Min: -4875.48   Med: -3264.8   Max: 17.84
Current: -111.88

FRA:1T3's Net Margin % is ranked worse than
52.22% of 946 companies
in the Biotechnology industry
Industry Median: -88.815 vs FRA:1T3: -111.88

Syndax Pharmaceuticals  (FRA:1T3) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Syndax Pharmaceuticals Net Margin % Related Terms

Syndax Pharmaceuticals Net Margin % Historical Data

* Premium members only.

The historical data trend for Syndax Pharmaceuticals's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syndax Pharmaceuticals Net Margin % Chart

Syndax Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.84 0.00 0.00 -1,346.13 -165.60

Syndax Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -423.34 -189.28 -132.36 -98.96 -65.79

FRA:1T3 vs CAPR, SLS, AGIO: Net Margin % Comparison

For the Biotechnology subindustry, Syndax Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Syndax Pharmaceuticals Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syndax Pharmaceuticals's Net Margin % distribution charts can be found below:

* The bar in red indicates where Syndax Pharmaceuticals's Net Margin % falls into.


FRA:1T3
25GF Score
Syndax Pharmaceuticals Inc FRA:1T3
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Syndax Pharmaceuticals Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Syndax Pharmaceuticals's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-243.75/147.189
=-165.60 %

Syndax Pharmaceuticals's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-36.912/56.107
=-65.79 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -65.79% mean?
Syndax Pharmaceuticals (FRA:1T3) has a Net Margin % of -65.79% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Syndax Pharmaceuticals and its competitors. According to the industry distribution chart, Syndax Pharmaceuticals ranks #494 out of 946 companies in the Biotechnology industry, placing it in the top 52.2%.
Is Syndax Pharmaceuticals' Net Margin % too high?
Syndax Pharmaceuticals' current Net Margin % is -65.79%. Based on the distribution chart, Syndax Pharmaceuticals ranks #494 out of 946 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Syndax Pharmaceuticals has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Syndax Pharmaceuticals' Net Margin % compare to CAPR and SLS?
According to the Biotechnology industry distribution chart, Syndax Pharmaceuticals ranks #494 out of 946 companies for Net Margin %. This places Syndax Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Syndax Pharmaceuticals and its competitors. Syndax Pharmaceuticals's current Net Margin % is -65.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syndax Pharmaceuticals stock overvalued right now?
Syndax Pharmaceuticals (FRA:1T3) has a current Net Margin % of -65.79%. The current Net Margin % is -65.79%. Syndax Pharmaceuticals' overall GF Score™ is 25/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Syndax Pharmaceuticals (FRA:1T3), the current Net Margin % is -65.79% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Syndax Pharmaceuticals Business Description

Other Exchanges SNDX:USA1T3:Germany
Address 730 Third Avenue, 9th Floor, New York, NY, USA, 10017
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
25GF Score

Get the complete analysis for FRA:1T3

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€17.43
Price